We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current IXC market cap is 6.46M. The company's latest EPS is AUD -0.0218 and P/E is -4.13.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 0 | 0 | 182k | 459k | 1.21M |
| Operating Income | -3.41M | -2.44M | -4.06M | -8.52M | -2.14M |
| Net Income | -3.36M | -2.28M | -3.95M | -7.75M | -1.64M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 26.42M | 32.74M | 29.49M | 22.8M | 6.12M |
| Total Liabilities | 2.02M | 659k | 1M | 1.57M | 432k |
| Total Equity | 24.4M | 32.08M | 28.48M | 21.23M | 5.69M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -1.6M | -1.68M | -3.38M | -6.87M | -2.44M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 15.73M | 8.09M | N/A | N/A | -14M |
| Market Cap | 6.46M |
| Price to Earnings Ratio | -4.13 |
| Price to Sales Ratio | 5.59 |
| Price to Cash Ratio | 1.12 |
| Price to Book Ratio | 1.19 |
| Dividend Yield | - |
| Shares Outstanding | 75.15M |
| Average Volume (1 week) | 107.65k |
| Average Volume (1 Month) | 56.79k |
| 52 Week Change | -57.00% |
| 52 Week High | 0.34 |
| 52 Week Low | 0.06 |
| Spread (Intraday) | 0.01 (6.98%) |
| Company Name | Invex Therapeutics Ltd |
| Address |
level 1, 38 rowland street perth, western australia 6008 |
| Website | https://www.invextherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
